InCarda Therapeutics
Newark
About InCarda Therapeutics
InCarda Therapeutics is a clinical-stage drug delivery company pioneering a novel approach of treating acute cardiovascular diseases/conditions by the inhalation route. Lead product is InRhythm, an inhaled formulation of an antiarrhythmic drug to treat acute paroxysmal atrial fibrillation events within minutes at home, at work, or anywhere. Completed Phase 1 and currently advancing lead product through Phase 2. InCarda Therapeutics was founded in Newark, California.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $100K – $500K
- Total funding: $77.9M
- Funding stage: Late Stage Venture
- Last round: Series C (Oct 2020)
- Website: incardatherapeutics.com
- Phone: +1 510 422 5522
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/incarda-therapeutics-27155 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.